Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study

被引：2
|
作者：
Panizo, Carlos [1 ]
Bekadja, Mohamed Amine [2 ]
Meddeb, Balkis [3 ]
Mendoza, Maria Rigoroso [4 ]
Truman, Matt [5 ]
Smith, Rodney [4 ]
Barate, Claudia [6 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] Univ Hosp Estab, Oran, Algeria
[3] Aziza Othmana Univ Hosp, Tunis, Tunisia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] F Hoffmann La Roche Ltd, Dee Why, Australia
[6] Univ Pisa, Pisa, Italy
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2971.2971
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2971
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Rituximab in the treatment of non-Hodgkin's lymphoma
    Hauptrock, Beate
    Hess, Georg
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 619 - 633
  • [22] Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
    Theodore-Oklota, Christina
    Humphrey, Louise
    Wiesner, Christof
    Schnetzler, Gabriel
    Hudgens, Stacie
    Campbell, Alicyn
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1767 - 1776
  • [23] An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK
    Ray, Joshua A.
    Carr, Emma
    Lewis, Gavin
    Marcus, Robert
    VALUE IN HEALTH, 2010, 13 (04) : 346 - 357
  • [24] Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study
    Martinelli, Giovanni
    Montoro, Juan
    Vanazzi, Anna
    Andreola, Giovanna
    Liptrott, Sarah
    Radice, Davide
    Negri, Mara
    Preda, Lorenzo
    Pruneri, Giancarlo
    Laszlo, Daniele
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (04) : 129 - 135
  • [25] First-Line Treatment of Hodgkin Lymphoma
    Engert, Andreas
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 : 17 - 18
  • [26] First-line treatment of Hodgkin lymphoma
    Federico, Massimo
    LEUKEMIA RESEARCH, 2018, 73 : S10 - S10
  • [27] BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA: EVIDENCE FROM A MULTICENTER, RETROSPECTIVE STUDY
    Mondello, P.
    Steiner, N.
    Willenbacher, W.
    Wasle, I.
    Zaja, F.
    Zambello, R.
    Visentin, A.
    Mauro, E.
    Ferrero, S.
    Ghione, P.
    Pitini, V.
    Cuzzocrea, S.
    Mian, M.
    HAEMATOLOGICA, 2016, 101 : 276 - 276
  • [28] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Wasle, Ines
    Zaja, Francesco
    Zambello, Renato
    Visentin, Andrea
    Mauro, Endri
    Ferrero, Simone
    Ghione, Paola
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1107 - 1114
  • [29] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
    Patrizia Mondello
    Normann Steiner
    Wolfgang Willenbacher
    Ines Wasle
    Francesco Zaja
    Renato Zambello
    Andrea Visentin
    Endri Mauro
    Simone Ferrero
    Paola Ghione
    Vincenzo Pitini
    Salvatore Cuzzocrea
    Michael Mian
    Annals of Hematology, 2016, 95 : 1107 - 1114
  • [30] A first-line treatment of low-grade non-Hodgkin's lymphoma with BACOP regimen
    Luisi, D
    Leva, T
    Malorgio, F
    Di Stefano, P
    Federico, M
    Silingardi, V
    Lombardo, M
    ANNALS OF ONCOLOGY, 2000, 11 : 53 - 53
12345